Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
MWN-AI** Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX) recently showcased its latest clinical and preclinical findings during the American Thoracic Society (ATS) 2025 International Conference held from May 16-21 in South San Francisco. Key presentations highlighted the antifibrotic activity of bexotegrast, Pliant's leading investigational drug, which is a dual inhibitor of ?V?6 and ?V?1 integrins.
In a prominent oral presentation, Dr. Johanna Schaub detailed the evaluation of bexotegrast's effects on human precision-cut lung slices (PCLS) derived from non-idiopathic pulmonary fibrosis (IPF) patients. The study revealed that bexotegrast significantly reduced the expression of genes associated with TGF-? signaling and fibrogenesis, impacting multiple fibroblast populations and alveolar type 1 cells, indicating its potential therapeutic benefits in various interstitial lung disease (ILD) subtypes.
Additionally, Dr. Erine Budi's poster presentation focused on a plasma proteome analysis that identified shared and unique biomarkers across multiple ILD subtypes, including IPF and scleroderma associated-ILD (SSc-ILD). These biomarkers may play a crucial role in enhancing clinical decision-making in ILD management.
Dr. Mahru An also presented work utilizing single-nuclei RNA sequencing to analyze how bexotegrast interacts with pathologic lung cell populations. This study demonstrated that bexotegrast effectively reduced the expression of profibrotic genes in specific cell types, surpassing the effects of nintedanib, particularly in cells expressing ?V?6 and ?V?1 integrins.
Pliant Therapeutics continues to advance its promising pipeline, with bexotegrast receiving Fast Track and Orphan Drug designations from the FDA, while also preparing for a Phase 1 study for its additional product candidates aimed at treating both fibrotic diseases and muscular dystrophies. For more details, visit Pliant’s website at www.PliantRx.com.
MWN-AI** Analysis
Pliant Therapeutics, Inc. (Nasdaq: PLRX) recently presented promising clinical and preclinical data at the American Thoracic Society (ATS) International Conference, highlighting the antifibrotic activity of their lead candidate, bexotegrast. Investors should take note of several critical developments that position Pliant favorably in the biopharmaceutical market.
The key takeaway from Dr. Johanna Schaub's oral presentation is the compelling efficacy of bexotegrast as a dual integrin inhibitor targeting ?V?6 and ?V?1 integrins. Its ability to reduce gene expression related to TGF-? signaling in various lung cell types suggests a meaningful therapeutic avenue for idiopathic pulmonary fibrosis (IPF) and potentially other interstitial lung diseases (ILDs). Given that IPF represents a significant market opportunity, driven by a growing prevalence and limited treatment options, bexotegrast's Fast Track and Orphan Drug Designations amplify its market potential.
Furthermore, the data on shared plasma biomarkers across ILD subtypes aids in understanding disease mechanisms and may help stratify patient populations for optimized treatment protocols. This level of biological insight can strengthen Pliant's positioning as they advance bexotegrast and other candidates, potentially leading to enhanced investor confidence in their pipeline.
Additionally, the findings presented by Dr. Mahru An underscore bexotegrast’s novel pharmacodynamic profile, differentiating it from existing therapies like nintedanib. If substantiated in larger trials, the unique mechanism could lead to competitive advantage and market differentiation.
In conclusion, Pliant Therapeutics presents itself as an attractive investment opportunity in the biotech sector, driven by innovative research that potentially enhances treatment outcomes for patients with fibrotic diseases. Investors should closely monitor upcoming clinical trial results, as the success of bexotegrast could significantly influence both the share price and the company's long-term growth trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025.
Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD Subtypes
In a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) patient lung explants. Results showed that bexotegrast, a dual inhibitor of ?V?6/?V?1 integrins, reduced expression of genes related to TGF-? signaling and fibrogenesis in alveolar type 1 (AT1) cells and multiple fibroblast subpopulations.
Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD Subtypes
In a poster presentation, Erine Budi, Ph.D., Senior Scientist II Translational Biology at Pliant Therapeutics, reviewed a comparative analysis assessing circulating plasma biomarkers of ILD in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis-ILD (RA-ILD), and scleroderma associated-ILD (SSc-ILD). Results identified biomarkers consistently dysregulated across multiple ILD subtypes that could assist in informing clinical decision making in ILD.
Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background Therapy
In a poster presentation, Mahru An, Ph.D., Director of Translational Sciences at Pliant Therapeutics, reviewed a single-nuclei RNAseq analysis of fibrotic human precision-cut lung slices comparing the pharmacodynamic effects of bexotegrast, a dual inhibitor of ?V?6 and ?V?1 integrins, alone, or in combination with nintedanib. Results showed that treatment with bexotegrast or nintedanib displayed distinct cell-specific pharmacodynamic profiles. In addition, bexotegrast alone, or in the presence of nintedanib, significantly reduced the expression of type I collagen and other profibrotic genes in aberrant basaloid cells (?V?6-expressing) and fibroblasts (?V?1-expressing), while treatment with nintedanib alone did not.
The presentation and posters presented at the 2025 ATS Conference are available by accessing the links above or on Pliant’s website under the Publications section at https://pliantrx.com/publications .
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of ? v ß 6 and ? v ß 1 integrins that is undergoing evaluation for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of ? v ß 8 and ? v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin ? 7 ? 1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com . Follow us on social media X , LinkedIn , and Facebook .
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ**
How does the dual inhibition of ?V?6 and ?V?1 integrins by Pliant Therapeutics Inc. (PLRX) position bexotegrast as a potential game changer in the treatment of idiopathic pulmonary fibrosis compared to existing therapies?
What are the implications of the circulating plasma biomarkers identified by Pliant Therapeutics Inc. (PLRX) for clinical decision-making in different subtypes of interstitial lung disease?
Can you elaborate on the distinct pharmacodynamic profiles observed with bexotegrast from Pliant Therapeutics Inc. (PLRX) when compared to nintedanib in the context of treating fibrotic lung diseases?
With both Fast Track and Orphan Drug Designations received by Pliant Therapeutics Inc. (PLRX) for bexotegrast, what strategic advantages might this provide in terms of development timelines and market entry?
**MWN-AI FAQ is based on asking OpenAI questions about Pliant Therapeutics Inc. (NASDAQ: PLRX).
NASDAQ: PLRX
PLRX Trading
-4.64% G/L:
$1.335 Last:
173,210 Volume:
$1.37 Open:
